Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Butorphanol (substance) |
Is a |
True |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
Nalbuphine (substance) |
Is a |
True |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
Product containing buprenorphine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
buprenorphin 300 µg/ml injektionsvæske, opløsning, ampul a 1 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
Pentazocine (substance) |
Is a |
True |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
Buprenorphine 70micrograms/hour transdermal patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
Buprenorphine 52.5micrograms/hour transdermal patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
Buprenorphine 35micrograms/hour transdermal patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
Product containing opioid receptor partial agonist (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Opioid receptor partial agonist |
Inferred relationship |
Some |
1 |
Product containing precisely buprenorphine (as buprenorphine hydrochloride) 400 microgram/1 each conventional release sublingual tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
Buprenorphine (as buprenorphine hydrochloride) 2 mg sublingual tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
Product containing precisely buprenorphine (as buprenorphine hydrochloride) 8 milligram/1 each conventional release sublingual tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
Buprenorphine (as buprenorphine hydrochloride) 200 microgram sublingual tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
Buprenorphine hydrochloride + naloxone hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
buprenorphinhydrochlorid 2 mg + naloxonhydrochlorid 0,5 mg sublingval resoriblet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
buprenorphinhydrochlorid 8 mg + naloxonhydrochlorid 2 mg sublingval resoriblet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
buprenorphin 35 µg/time depotplaster |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
buprenorphin 52,2 µg/time depotplaster |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
buprenorphin 70 µg/time depotplaster |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
Product containing dezocine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
dezocin 5 mg/ml injektionsvæske, opløsning, ampul a 1 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
dezocin 10 mg/ml injektionsvæske, opløsning, ampul a 1 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
dezocin 15 mg/ml injektionsvæske, opløsning, ampul a 1 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
Dezocine |
Is a |
True |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
Buprenorphine (substance) |
Is a |
True |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
Butorphanol tartrate |
Is a |
True |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
Pentazocine lactate |
Is a |
True |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
Pentazocine hydrochloride |
Is a |
True |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
Norbuprenorphine (substance) |
Is a |
True |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
Buprenorphine hydrochloride |
Is a |
True |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|
Nalbuphine hydrochloride |
Is a |
True |
Opioid receptor partial agonist |
Inferred relationship |
Some |
|